Current Breast Cancer Reports

, Volume 6, Issue 2, pp 121–131

Use of Exogenous Hormones and Risks of Breast and Ovarian Cancers in BRCA1/2 Mutation Carriers; Methodological and Clinical Considerations

  • Lieske H. Schrijver
  • Susanne Jansen
  • Frederieke H. van der Baan
  • Matti A. Rookus
Risk, Prevention, and Screening (TA Patel, Section Editor)

Abstract

Risks of breast and ovarian cancer among BRCA1/2 mutation carriers are high, even for the young. Recommendations for use of exogenous hormones designed for BRCA1/2 mutation carriers may therefore be appropriate. Here we review studies on the associations between oral contraceptives (OC) and hormone-replacement therapy (HRT) use and the risks of breast or ovarian cancer among BRCA1/2 carriers. Almost all studies had a retrospective design. OC use reduced the risk of ovarian cancer, but high uptake of bilateral prophylactic oophorectomy (BPO) renders this protective association hardly relevant for most BRCA1/2 mutation carriers. As long as a positive association between OC use and breast cancer risk cannot be ruled out, it may be necessary to consider alternative methods of contraception. Evidence on HRT is scarce. Assuming similar associations for BRCA1/2 carriers as for the general population it may be advisable to use HRT for a short period only.

Keywords

Breast cancer Ovarian cancer BRCA1/2 mutation carriers Oral contraceptive Hormone replacement therapy HRT review 

References

  1. 1.
    Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347:1713–1727.Google Scholar
  2. 2.
    Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22:1931–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122:139–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350:1047–1059.Google Scholar
  5. 5.
    Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170:12–23.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353–68.PubMedCrossRefGoogle Scholar
  7. 7.
    Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296–305.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol. 2008;108:641–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA. 2009;302:298–305.PubMedCrossRefGoogle Scholar
  10. 10.
    Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2011;22:1075–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010;340:c927.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev. 2002;26:23–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer. 2005;41:2312–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev. 2008;17:3170–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 1997;57:3678–81.PubMedGoogle Scholar
  16. 16.
    Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14:350–6.PubMedCrossRefGoogle Scholar
  17. 17.
    McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160:613–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control. 2003;14:439–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100:1361–7.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat. 2010;120:175–83.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006;15:1863–70.PubMedCrossRefGoogle Scholar
  22. 22.
    Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Sade RB, Chetrit A, Figer A, Papa MZ, Flex D, Rizel S, et al. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. Eur J Cancer. 2006;42:650–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol. 2006;100:83–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014;143:579–86.PubMedCrossRefGoogle Scholar
  26. 26.
    McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet Oncol. 2007;8:26–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94:1773–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998;339:424–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29:1–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25:3831–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2009;18:601–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Breast Cancer Res Treat. 2011;129:557–63.PubMedCrossRefGoogle Scholar
  33. 33.
    Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB. Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry. Br J Cancer. 2014;110:1074–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 2004;91:1911–5.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013;1–514.Google Scholar
  37. 37.
    Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46:2275–84.PubMedCrossRefGoogle Scholar
  38. 38.
    Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31:4188–98.PubMedCrossRefGoogle Scholar
  39. 39.
    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012;13:1523–35.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122:11–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol 2013.Google Scholar
  43. 43.
    Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. JAMA Intern Med. 2013;173:96–103.PubMedCrossRefGoogle Scholar
  44. 44.
    Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, et al. Risk-reducing mastectomy in BRCA1/2 mutation carriers: Factors influencing uptake and timing. Maturitas. 2014;77:180–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Gronwald J, Byrski T, Huzarski T, Cybulski C, Sun P, Tulman A, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat. 2006;95:105–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lieske H. Schrijver
    • 1
  • Susanne Jansen
    • 1
  • Frederieke H. van der Baan
    • 1
  • Matti A. Rookus
    • 1
  1. 1.Department of Epidemiology, Division of Psychosocial Research and EpidemiologyNetherlands Cancer InstituteAmsterdamNetherlands

Personalised recommendations